Cabazitaxel in Patients With Recurrent Ovarian Cancer After Failure of Standard Therapy - A Phase II Trial
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 26
- 试验地点
- 1
- 主要终点
- Number of patients alive and without progression after three months of treatment
研究概览
简要总结
Many ovarian cancer patients have been offered different standard cytostatics and gradually develop chemo-resistance. However, a considerable fraction of these patients are still in good general health and have a strong wish for further treatment.
Cabazitaxel (Jevtana®) is a new taxane with effect in breast and prostatic cancer. In both tumors it has shown effect in patients refractory to docetaxel. Therefore, it could be anticipated that cabazitaxel may also have an effect in chemo-resistant ovarian cancer.
The aim of the study is to investigate whether cabazitaxel could be a reasonable treatment option in patients with chemo-resistant and refractory ovarian cancer with regard to effect and toxicity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed epithelial, primary fallopian or primary peritoneal cancer.
- •Platinum resistant ovarian cancer with at least two previous cytostatic regimens or platinum-refractory disease defined as progression while receiving the last line of platinum based therapy or within 4 weeks of last platinum dose
- •Progression on previous treatment.
- •Measurable disease by RECIST 1.1 or evaluable by GCIG CA-125 criteria
- •Age ≥ 18 years.
- •Performance status 0-
- •Adequate bone marrow function, liver function, and renal function (within 7 days prior to inclusion):
- •Neutrophils (ANC) ≥ 1.5 * 10^9/l
- •Platelet count ≥ 100 * 10^9/l
- •Hemoglobin ≥ 9.0 g/dL or ≥ 5.6 mmol/l
- •Serum bilirubin ≤ 1.0 * ULN
- •Serum transaminase ≤ 2.5 * ULN
- •Serum creatinine ≤ 1.5 ULN (at creatinine above 1.5 x ULN measured GFR must be at least 50 ml / min)
- •Remaining life expectancy of at least 3 months
- •Written informed consent
排除标准
- •History of severe hypersensitivity reaction (≥grade 3) to taxol.
- •History of severe hypersensitivity reaction (≥grade 3) to polysorbate 80 containing drugs.
- •Allergy to the active substance or any of the auxiliary agents.
- •Concurrent or planned treatment with strong inhibitors or strong inducers of cytochrome P450 3A4/5 (a 2-week wash-out period is necessary for patients who are already on these treatments)
- •Neuropathy grade ≥
- •Pregnant or breast-feeding patients. For fertile women a negative pregnancy test at screening is mandatory.
- •Fertile patients not willing to use effective methods of contraception during treatment and for 6 months after the end of treatment.
- •Other malignant diseases within 5 years prior to inclusion in the study, except basal cell or squamous cell carcinoma of the skin and cervical carcinoma-in-situ.
- •Other experimental therapy or participation in another clinical trial within 28 days prior to treatment initiation.
- •History of any chronic medical or psychiatric condition or laboratory abnormality that is not medically controlled or in the opinion of the investigator may increase the risks associated with study drug administration. (e.g. diabetes, cardiac diseases, hypertension, renal, thyroid or liver disease).
- •Vaccination with yellow fever vaccine or any live attenuated vaccine during the treatment.
研究组 & 干预措施
Cabazitaxel
25 mg/m2 administered as a one hour intravenous infusion on day 1 of a 3-week cycle.
Treatment continues until progression or unacceptable toxicity.
干预措施: Cabazitaxel (Drug)
结局指标
主要结局
Number of patients alive and without progression after three months of treatment
时间窗: 3 months after start of treatment
次要结局
- Overall survival(Every three months up to 24 months)
- Response rate(Every 9 weeks from date of enrollment until the date of first documented progression or date of death of any cause, whichever came first. Assessed up to 24 months)
- Progression free survival(Every 9 weeks from date of enrollment until the date of first documented progression or date of death of any cause, whichever came first. Assessed up to 24 months)